NO300253B1 - Anvendelse av 1,4-dihydropyridiner ved diabetes - Google Patents
Anvendelse av 1,4-dihydropyridiner ved diabetes Download PDFInfo
- Publication number
- NO300253B1 NO300253B1 NO922795A NO922795A NO300253B1 NO 300253 B1 NO300253 B1 NO 300253B1 NO 922795 A NO922795 A NO 922795A NO 922795 A NO922795 A NO 922795A NO 300253 B1 NO300253 B1 NO 300253B1
- Authority
- NO
- Norway
- Prior art keywords
- nimodipine
- treated
- curve
- diabetic
- streptozotocin
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 33
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 title claims abstract description 7
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims abstract description 44
- 229960000715 nimodipine Drugs 0.000 claims abstract description 44
- 239000003814 drug Substances 0.000 claims abstract description 5
- 201000001119 neuropathy Diseases 0.000 claims description 8
- 230000007823 neuropathy Effects 0.000 claims description 8
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000006501 nitrophenyl group Chemical group 0.000 claims description 2
- 210000000578 peripheral nerve Anatomy 0.000 abstract description 12
- 230000006378 damage Effects 0.000 abstract description 7
- 230000002213 calciumantagonistic effect Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 14
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 14
- 229960001052 streptozocin Drugs 0.000 description 14
- 230000007830 nerve conduction Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 230000001953 sensory effect Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 9
- 101000981886 Homo sapiens Lengsin Proteins 0.000 description 7
- 102100024144 Lengsin Human genes 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 101001063370 Homo sapiens Legumain Proteins 0.000 description 6
- 102100030985 Legumain Human genes 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 5
- 208000033808 peripheral neuropathy Diseases 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003288 aldose reductase inhibitor Substances 0.000 description 2
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- -1 -isopropyl ester Chemical class 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4125116A DE4125116A1 (de) | 1991-07-30 | 1991-07-30 | Verwendung von 1,4-dihydropyridinen bei diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO922795D0 NO922795D0 (no) | 1992-07-15 |
| NO922795L NO922795L (no) | 1993-02-01 |
| NO300253B1 true NO300253B1 (no) | 1997-05-05 |
Family
ID=6437256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO922795A NO300253B1 (no) | 1991-07-30 | 1992-07-15 | Anvendelse av 1,4-dihydropyridiner ved diabetes |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0525537B1 (sk) |
| JP (1) | JP3381198B2 (sk) |
| KR (1) | KR930001908A (sk) |
| AT (1) | ATE111732T1 (sk) |
| AU (1) | AU659177B2 (sk) |
| CA (1) | CA2074709A1 (sk) |
| CZ (1) | CZ281712B6 (sk) |
| DE (2) | DE4125116A1 (sk) |
| DK (1) | DK0525537T3 (sk) |
| ES (1) | ES2059181T3 (sk) |
| HU (1) | HU208632B (sk) |
| IE (1) | IE65109B1 (sk) |
| IL (1) | IL102648A (sk) |
| MX (1) | MX9204423A (sk) |
| NO (1) | NO300253B1 (sk) |
| RU (1) | RU2043102C1 (sk) |
| SK (1) | SK238692A3 (sk) |
| TW (1) | TW202388B (sk) |
| ZA (1) | ZA925686B (sk) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863360A (en) * | 1988-01-15 | 1989-09-05 | Rogers Industrial Products | Bag control mechanism for tire press |
-
1991
- 1991-07-30 DE DE4125116A patent/DE4125116A1/de not_active Withdrawn
-
1992
- 1992-07-07 TW TW081105356A patent/TW202388B/zh active
- 1992-07-15 NO NO922795A patent/NO300253B1/no unknown
- 1992-07-17 DK DK92112201.6T patent/DK0525537T3/da active
- 1992-07-17 AT AT92112201T patent/ATE111732T1/de not_active IP Right Cessation
- 1992-07-17 ES ES92112201T patent/ES2059181T3/es not_active Expired - Lifetime
- 1992-07-17 DE DE59200530T patent/DE59200530D1/de not_active Expired - Fee Related
- 1992-07-17 EP EP92112201A patent/EP0525537B1/de not_active Expired - Lifetime
- 1992-07-22 AU AU20484/92A patent/AU659177B2/en not_active Ceased
- 1992-07-27 IL IL102648A patent/IL102648A/xx not_active IP Right Cessation
- 1992-07-27 CA CA002074709A patent/CA2074709A1/en not_active Abandoned
- 1992-07-29 ZA ZA925686A patent/ZA925686B/xx unknown
- 1992-07-29 IE IE922467A patent/IE65109B1/en not_active IP Right Cessation
- 1992-07-29 MX MX9204423A patent/MX9204423A/es not_active IP Right Cessation
- 1992-07-29 KR KR1019920013561A patent/KR930001908A/ko not_active Application Discontinuation
- 1992-07-29 RU SU925052306A patent/RU2043102C1/ru active
- 1992-07-29 JP JP22094392A patent/JP3381198B2/ja not_active Expired - Fee Related
- 1992-07-30 CZ CS922386A patent/CZ281712B6/cs unknown
- 1992-07-30 HU HU9202484A patent/HU208632B/hu not_active IP Right Cessation
- 1992-07-30 SK SK2386-92A patent/SK238692A3/sk unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ281712B6 (cs) | 1996-12-11 |
| NO922795D0 (no) | 1992-07-15 |
| EP0525537A1 (de) | 1993-02-03 |
| AU659177B2 (en) | 1995-05-11 |
| NO922795L (no) | 1993-02-01 |
| IE65109B1 (en) | 1995-10-04 |
| IL102648A (en) | 1997-03-18 |
| HUT63330A (en) | 1993-08-30 |
| JPH06157314A (ja) | 1994-06-03 |
| MX9204423A (es) | 1993-01-01 |
| HU9202484D0 (en) | 1992-10-28 |
| TW202388B (sk) | 1993-03-21 |
| JP3381198B2 (ja) | 2003-02-24 |
| KR930001908A (ko) | 1993-02-22 |
| HU208632B (en) | 1993-12-28 |
| SK238692A3 (en) | 1995-11-08 |
| CZ238692A3 (en) | 1994-01-19 |
| EP0525537B1 (de) | 1994-09-21 |
| CA2074709A1 (en) | 1993-01-31 |
| DE59200530D1 (de) | 1994-10-27 |
| DK0525537T3 (da) | 1995-02-20 |
| IL102648A0 (en) | 1993-01-14 |
| ES2059181T3 (es) | 1994-11-01 |
| ATE111732T1 (de) | 1994-10-15 |
| AU2048492A (en) | 1993-02-04 |
| RU2043102C1 (ru) | 1995-09-10 |
| IE922467A1 (en) | 1993-02-10 |
| ZA925686B (en) | 1993-04-28 |
| DE4125116A1 (de) | 1993-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pacchetti et al. | “Off” painful dystonia in Parkinson's disease treated with botulinum toxin | |
| AU743609B2 (en) | Use of cholinesterase inhibitors to treat disorders of attention | |
| Birkmayer et al. | Implications of combined treatment with'Madopar'and L-deprenil in Parkinson's disease: a long-term study | |
| US20100144858A1 (en) | Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator | |
| JP2549643B2 (ja) | 神経変性症の予防及び治療における特異的ｎーメチルーｄーアスパラギン酸エステルレセプター拮抗剤としての用途 | |
| JP5116665B2 (ja) | 口腔投与のためのアポモルフィンの薬学的配合物 | |
| CA2137285A1 (en) | Alpha-2-adrenergic agonists for treating presbyopia | |
| WO2007108541A1 (ja) | キサンタンガムおよびブドウ糖を含有する眼科用組成物 | |
| CN1418100A (zh) | 控制视野丧失的具有5－ht活性的化合物 | |
| JPH11501282A (ja) | コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体 | |
| JP2655706B2 (ja) | 抗パーキンソン病エルゴリン誘導体 | |
| US20110218206A1 (en) | Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use | |
| US4782077A (en) | Taliscanin and other aristolactams for treating neurological disorders, Parkinson's disease, Alzheimer disease and impotence | |
| CA2398261A1 (en) | Treating allergic and inflammatory conditions | |
| NO300253B1 (no) | Anvendelse av 1,4-dihydropyridiner ved diabetes | |
| JPH01502829A (ja) | 緑内障または高眼圧の局所治療用組成物 | |
| MX9805317A (es) | Agente para la profilaxis y el tratamiento de complicaciones diabeticas. | |
| US5438144A (en) | Use of 1,4-dihydropyridines in diabetes | |
| EP2968227B1 (en) | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | |
| EP0984787B1 (fr) | Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux | |
| JP2004203836A (ja) | 眼科用局所適用製剤 | |
| WO2024010045A1 (ja) | 疼痛抑制剤 | |
| WO1996028161A1 (fr) | Utilisation des derives de 2-[4-(azolylbutyl)-piperazinyl-methyl]-benzimidazole pour le traitement de la conjonctivite allergique | |
| JP2001504100A (ja) | 緑内障を治療するための炭酸脱水素酵素阻害剤とプロスタグランジンとの組合せの使用 | |
| Teräväinen et al. | Initial treatment of parkinsonism with 8‐alpha‐amino‐ergoline |